But the company has recently debuted a new product, called EXIS (short for Externalized Immune System): a lab-grown version of a human lymph node. In addition, the company will add Kevin Chapman, Celesta advisor and former CSO of Berkeley Lights, as Chief Scientific Officer. The company can create 1,200 organoids from one blood draw, challenge those immune systems with a particular antigen, and see what each immune system comes up with. Matheu says the company has developed antibodies responsive to SARS-CoV-2, Influenza A and Marburg Hemorrhagic Fever (these results haven’t been published). The company plans to use this round to move from an R&D driven company to a product focused one – which means developing more drug partnerships, and demonstrating the platform’s capability. That may occur through collaboration with a pharmaceutical partner, though the company hasn’t ruled out creating a drug pipeline of its own. “Our company’s edge is that [EXIS] is out of the box fully human.” Prellis Biologics, founded in 2016,